Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Have received a dose of lebrikizumab.
Is currently on allergen immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy (SCIT/SLIT) for ≥3 years prior to randomization are eligible, if they were not on a maintenance allergen immunotherapy (AIT) regimen.
Have received treatment with any rescue medication during the screening and/or run-in period.
Have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:
Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 4 weeks of the maintenance period.
Anticipates significant changes in their daily environmental exposure
Has a known history of recurrent acute or chronic sinusitis,
Female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.
Primary purpose
Allocation
Interventional model
Masking
450 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal